Typhoid (Enteric) Fever - Treatment

Typhoid fever (caused by Salmonella Typhi, or the milder paratyphoid A/B/C) is treated with antibiotics; supportive care and prompt recognition of complications are equally important. Treatment choice increasingly depends on local resistance patterns, since antimicrobial resistance is now the dominant factor driving therapy decisions (Harrison's Principles of Internal Medicine, 22e; Tintinalli's Emergency Medicine).

First-line antibiotic options

Drug	Route	Typical use
Azithromycin	Oral	First-line for uncomplicated disease, especially where fluoroquinolone/MDR resistance is common (South Asia)
Ceftriaxone or cefotaxime (3rd-gen cephalosporins)	IV/IM	First-line for drug-sensitive typhoid, especially hospitalized/moderate-severe cases
Cefixime	Oral	Oral cephalosporin alternative, often in children
Ciprofloxacin / other fluoroquinolones	Oral	Effective only against fully fluoroquinolone-susceptible strains - resistance is now widespread across South/Southeast Asia, so these should not be used empirically without susceptibility data

Duration of treatment depends on severity - uncomplicated disease is generally treated for about 7-14 days, with shorter courses (5-7 days) sometimes used for azithromycin; severe or complicated disease requires longer IV therapy (per Tintinalli's Emergency Medicine, p. 3387; Park's Textbook of Preventive and Social Medicine).

Resistance-driven approach (critical)

Multidrug-resistant (MDR) strains (resistant to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole) have existed since the 1980s - these three older agents are now considered unreliable/second-line only.
Fluoroquinolone-resistant strains have spread widely from the Indian subcontinent, making ciprofloxacin an unsafe empirical first choice in returning travelers from that region.
Extensively drug-resistant (XDR) S. Typhi has caused a large ongoing epidemic in Pakistan since 2016, resistant to ceftriaxone, ampicillin, ciprofloxacin, and TMP-SMX - these isolates remain susceptible only to azithromycin and carbapenems (Harrison's 22e; Red Book 2021, p. 1724). Azithromycin resistance has now also emerged in some regions where it's used as first-line therapy, so susceptibility testing matters wherever feasible.
For patients not improving on carbapenem monotherapy in suspected XDR infection, adding azithromycin has been reported as beneficial.
A travel history to Pakistan, South Asia, or Southeast Asia should specifically raise concern for MDR/XDR strains and shift empiric choice toward azithromycin ± carbapenem while awaiting cultures.

Severe / complicated disease

Suspected typhoid encephalopathy, meningitis, or septic shock: add IV dexamethasone to antibiotics (Tintinalli's Emergency Medicine, p. 3387).
Intestinal perforation or significant GI bleeding (occurs in ~1% and ~6% of hospitalized cases respectively, typically in the 3rd-4th week of illness): requires broadened antibiotic coverage for polymicrobial peritonitis, fluid resuscitation, blood transfusion, and surgical intervention (bowel resection) (Harrison's Principles of Internal Medicine, 22e).
Supportive care: IV rehydration, antipyretics, and monitoring for relapse (which can occur even after clinical improvement).
Untreated typhoid carries 10-20% mortality, mostly in young children; prompt antibiotics substantially reduce this.

Chronic carriage (2-5% of patients)

Fluoroquinolone-susceptible carriage: 4-week course of oral ciprofloxacin (or another fluoroquinolone), ~80% eradication rate.
Fluoroquinolone-resistant carriage: 4-week oral azithromycin (limited clinical data) or oral amoxicillin (lower eradication rates) if ampicillin-susceptible.
If gallstones/renal or bladder stones are present, eradication often needs antibiotics plus surgical correction (cholecystectomy, stone removal).

Evidence check

A 2024 systematic review of RCTs (PMID: 39623850) comparing oral azithromycin against other antimicrobials across all age groups supports azithromycin's clinical efficacy for typhoid treatment, consistent with the guidance above. No conflicting recent meta-analyses were found; the main 2025 systematic reviews in this space focus on typhoid conjugate vaccines for prevention (PMID: 40326553, 41125003) rather than treatment, so they don't change the treatment recommendations.

Key caveat

Always guide therapy with blood/stool/bone-marrow culture and susceptibility testing when available - empiric choice should be informed by regional resistance data and travel history, since older first-line drugs (ampicillin, chloramphenicol, TMP-SMX, and increasingly fluoroquinolones) can no longer be assumed effective.

If you want, I can go deeper into pediatric dosing, pregnancy-specific considerations, or diagnostic workup (blood/bone marrow cultures, Widal test limitations).

This is a shared conversation. Sign in to Orris to start your own chat.